首页> 外文期刊>American Journal of Kidney Diseases: The official journal of the National Kidney Foundation >Correlation of pre-existing vascular pathology with arteriovenous graft outcomes in hemodialysis patients
【24h】

Correlation of pre-existing vascular pathology with arteriovenous graft outcomes in hemodialysis patients

机译:血液透析患者既有血管病理与动静脉移植物预后的相关性

获取原文
获取原文并翻译 | 示例
       

摘要

Background: Arteriovenous grafts (AVGs) are prone to neointimal hyperplasia leading to AVG failure. We hypothesized that pre-existing pathologic abnormalities of the vessels used to create AVGs (including venous intimal hyperplasia, arterial intimal hyperplasia, arterial medial fibrosis, and arterial calcification) are associated with inferior AVG survival. Study Design: Prospective observational study. Setting & Participants: Patients with chronic kidney disease undergoing placement of a new AVG at a large medical center who had vascular specimens obtained at the time of surgery (n = 76). Predictor: Maximal intimal thickness of the arterial and venous intima, arterial medial fibrosis, and arterial medial calcification. Outcome & Measurements: Unassisted primary AVG survival (time to first intervention) and frequency of AVG interventions. Results: 55 patients (72%) underwent interventions and 148 graft interventions occurred during 89.9 years of follow-up (1.65 interventions per graft-year). Unassisted primary AVG survival was not associated significantly with arterial intimal thickness (HR, 0.72; 95% CI, 0.40-1.27; P = 0.3), venous intimal thickness (HR, 0.64; 95% CI, 0.37-1.10; P = 0.1), severe arterial medial fibrosis (HR, 0.58; 95% CI, 0.32-1.06; P = 0.6), or severe arterial calcification (HR, 0.68; 95% CI, 0.37-1.31; P = 0.3). The frequency of AVG interventions per year was associated inversely with arterial intimal thickness (relative risk [RR], 1.99; 95% CI, 1.16-3.42; P < 0.001 for thickness <10 vs >25 μm), venous intimal thickness (RR, 2.11; 95% CI, 1.39-3.20; P < 0.001 for thickness <5 vs >10 μm), arterial medial fibrosis (RR, 3.17; 95% CI, 1.96-5.13; P < 0.001 for fibrosis <70% vs ≥70%), and arterial calcification (RR, 2.12; 95% CI, 1.31-3.43; P = 0.001 for <10% vs ≥10% calcification). Limitations: Single-center study. Study may be underpowered to demonstrate differences in unassisted primary AVG survival. Conclusions: Pre-existing vascular pathologic abnormalities in patients with chronic kidney disease may not be associated significantly with unassisted primary AVG survival. However, vascular intimal hyperplasia, arterial medial fibrosis, and arterial calcification may be associated with a decreased frequency of AVG interventions.
机译:背景:动静脉移植物(AVG)易于发生新内膜增生,导致AVG衰竭。我们假设用于创建AVG的血管的先前存在的病理异常(包括静脉内膜增生,动脉内膜增生,动脉内侧纤维化和动脉钙化)与AVG的存活率较低有关。研究设计:前瞻性观察研究。场所和参与者:患有慢性肾脏疾病的患者正在一家大型医疗中心接受新的AVG植入,他们在手术时获得了血管标本(n = 76)。预测因素:动脉和静脉内膜的最大内膜厚度,动脉内纤维化和动脉内钙化。结果与测量:无辅助的原发性AVG生存(首次干预的时间)和AVG干预的频率。结果:55名患者(72%)接受了干预,在89.9年的随访期间(每移植年1.65次)进行了148例移植手术。无辅助的原发性AVG生存与动脉内膜厚度(HR,0.72; 95%CI,0.40-1.27; P = 0.3),静脉内膜厚度(HR,0.64; 95%CI,0.37-1.10; P = 0.1)无关。 ,严重的动脉内侧纤维化(HR,0.58; 95%CI,0.32-1.06; P = 0.6)或严重的动脉钙化(HR,0.68; 95%CI,0.37-1.31; P = 0.3)。每年AVG干预的频率与动脉内膜厚度相关(相对危险度[RR] 1.99; 95%CI为1.16-3.42; P <0.001,厚度<10 vs> 25μm),静脉内膜厚度(RR, 2.11; 95%CI,1.39-3.20;厚度<5 vs> 10μm时P <0.001),动脉内纤维化(RR,3.17; 95%CI,1.96-5.13;纤维化<70%vs≥70时P <0.001 )和动脉钙化(RR,2.12; 95%CI,1.31-3.43; P = 0.001(钙化<10%vs≥10%))。局限性:单中心研究。研究可能不足以证明无助的原发性AVG生存率的差异。结论:慢性肾脏病患者预先存在的血管病理异常可能与无辅助的原发性AVG生存没有显着相关。但是,血管内膜增生,动脉内侧纤维化和动脉钙化可能与AVG干预的频率降低有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号